Some aspects on the management of hemophilia.
Aledort
L M
LM
Mount Sinai School of Medicine, New York, NY 10029-6574, USA.
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D005060:Europe / Q000453:epidemiology; D005169:Factor VIII / Q000032:analysis / Q000191:economics / Q000627:therapeutic use; D005260:Female; D017048:Health Care Costs; D006395:Hemarthrosis / Q000000981:diagnostic imaging / Q000191:economics / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D006467:Hemophilia A / Q000150:complications / Q000191:economics / Q000453:epidemiology / Q000628:therapy*; D006801:Humans; D007223:Infant; D007260:Infusion Pumps / Q000009:adverse effects / Q000191:economics; D007275:Injections, Intravenous / Q000191:economics; D007564:Japan / Q000453:epidemiology; D008297:Male; D011859:Radiography; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D014841:von Willebrand Factor / Q000032:analysis
D014841:von Willebrand Factor; D005169:Factor VIII; D003894:Deamino Arginine Vasopressin